计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Scriptaid, 组蛋白去乙酰化酶 1 抑制剂；组蛋白去乙酰化酶 2 抑制剂；组蛋白去乙酰化酶 3 抑制剂；组蛋白去乙酰化酶 4 抑制剂；组蛋白去乙酰化酶 5 抑制剂；组蛋白去乙酰化酶 6 抑制剂；组蛋白去乙酰化酶 7 抑制剂；组蛋白去乙酰化酶 8 抑制剂；组蛋白去乙酰化酶 9 抑制剂
有货
为什么选择此级别
Moligand™ 级 ，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Scriptaid 是一种组蛋白去乙酰化酶 (HDAC) 抑制剂，可用于癌症研究。Scriptaid 也是一种抗病毒药的敏化剂，可用于与爱泼斯坦-巴尔病毒 (EBV) 相关的淋巴瘤的研究。
Information
Scriptaid Scriptaid (GCK 1026) is an inhibitor of HDAC . It shows a greater effect on acetylated H4 than H3.
In vitro
Scriptaid (6 μM) results in a >100-fold increase in histone acetylation in PANC-1 cell. Scriptaid (8 μM) is not lethal to PANC-1 cell and has limited effects (80% survival) on MDAMB-468. Scriptaid increases the transcription of pCMVb, p6SBE-luc and p6MBE-luc independent of a positive inducer of transcription. Scriptaid is capable of inducing high expression of p6MBE-luc, pCMVb, and pUB6/V5-LacZ, driven by viral (SV40 and CMV) or human (ubiquitin c, UB6) promoters, which do not depend on the specificity of the enhancer (SBE versus MBE), the type of promoter (viral versus cellular), the product of the reporter gene (luciferase versus b-gal), nor on the integration status of the reporter construct. Scriptaid induces high rates of somatic cell nuclear transfer (SCNT) oocytes development to the blastocyst stage and allowed full-term development (3.4, 4.2, 7.6, 6.8, and 4.1%) with all concentrations (50, 100, 250, 500, and 2000 nM respectively). Scriptaid improves the full-term development of cloned B6D2F1embryos in a dose-dependent manner with the maximum effect at 250 nM. Scriptaid enables the clone of all the important inbred mouse strains, such as C57BL/6, C3H/He, DBA/2, and 129/Sv. Scriptaid treatment enhances newly synthesized mRNA levels in cloned embryos. 250 nM Scriptaid treated for up to 48 h, does not inhibit the development of ICSI-fertilized embryos. Scriptaid inhibits T. gondii tachyzoite proliferation with IC50 of 39 nM. Scriptaid (0.225 μM) completely protects the HS68 monolayers from T. gondii tachyzoite. Scriptaid inhibits growth of ER negative cell lines, MDA-MB-231, MDA-MB-435 and Hs578t with IC50 of 0.5-1.0 μg/mL after 48 h treatment. 1 μg/ml Scriptaid treated for 48 h induces an accumulation of both acetylated H3 and acetylated H4 histone tail proteins, and a maximal of 20,000-fold increase of ER mRNA transcript. Scriptaid inhibits the proliferation and viability of the Ishikawa endometrial cancer cell line, and the SK-OV-3 ovarian cancer cell line with IC50 of 9 μM and 55 μM, respectively, while the normal human endometrial epithelial cells shows little sensitivity. Endometrial cancer cells and ovarian cancer cells cultured for 2 days in the presence of Scriptaid shows an accumulation in the G0/G1 phase (5 μM of Scriptaid) and G2/M phase (10 μM of Scriptaid) of the cell cycle, with a concomitant decrease in the proportion of those in the S phase. 10 μM of Scriptaid induces a 56.1% of apoptotic Ishikawa cells with loss of mitochondrial membrane potential, and decreased levels of cyclin A and bcl-2 levels by 50% and 20%, respectively.
In vivo
Scriptaid elicits a dose-dependent decrease in lesion size (a maximal decrease of 45%) at 1.5 to 5.5 mg/kg and a concomitant attenuation in motor and cognitive deficits when delivered 30 minutes postinjury in a model of mode rate TBI. Comparable protection is achieved even when treatment is delayed to 12 h postinjury. The protection of motor and cognitive functions is long lasting, as similar improvements are detected 35 days postinjury. Scriptaid induces an increase in surviving neurons (42%), as well as the number/length of their processes within the CA3 region of the hippocampus and the pericontusional cortex. Scriptaid treatment prevents the decrease in phospho-AKT (p-AKT) and phosphorylated phosphatase and tensin homolog deleted on chromosome 10 ( p-PTEN) induced by TBI in cortical and CA3 hippocampal neurons. Scriptaid treatment (3.5 mg/kg) clearly inhibits tumor growth in a human breast cancer xenograft MDA-MB-231 model, reducing tumor volume by 75%.
Cell Data
cell lines：
Concentrations：~10 μg/mL
Incubation Time：3 days
Powder Purity:≥99%
规格
别名
脚本帮助
英文别名
GCK 1026 | 1H-Benz[de]isoquinoline-2(3H)-hexanamide, N-hydroxy-1,3-dioxo-
规格或纯度
Moligand™, 10mM in DMSO
英文名称
Scriptaid
生化机理
Scriptaid （GCK 1026）是一种 HDAC 抑制剂。它对乙酰化 H4 的作用大于 H3。
储存条件
-80℃储存
运输条件
特低温运输
作用类型
抑制剂
作用机制
组蛋白去乙酰化酶 1 抑制剂；组蛋白去乙酰化酶 2 抑制剂；组蛋白去乙酰化酶 3 抑制剂；组蛋白去乙酰化酶 4 抑制剂；组蛋白去乙酰化酶 5 抑制剂；组蛋白去乙酰化酶 6 抑制剂；组蛋白去乙酰化酶 7 抑制剂；组蛋白去乙酰化酶 8 抑制剂；组蛋白去乙酰化酶 9 抑制剂
名称和识别符
分子类型
小分子
Isomeric SMILES
C1=CC2=C3C(=C1)C(=O)N(C(=O)C3=CC=C2)CCCCCC(=O)NO
PubChem CID
分子量
326.35
技术文档
高级数据
关联靶点（人）
HDAC4
Tclin
组蛋白去乙酰化酶4(Histone deacetylase 4)
(2 活性数据)
HDAC6
Tclin
组蛋白去乙酰化酶6(Histone deacetylase 6)
(6 活性数据)
HDAC1
Tclin
组蛋白去乙酰化酶1(Histone deacetylase 1)
(5 活性数据)
HDAC7
Tclin
组蛋白去乙酰化酶7(Histone deacetylase 7)
(1 活性数据)
HDAC11
Tclin
组蛋白去乙酰化酶11(Histone deacetylase 11)
(1 活性数据)
HDAC9
Tclin
组蛋白去乙酰化酶9(Histone deacetylase 9)
(2 活性数据)
HDAC2
Tclin
组蛋白去乙酰化酶2(Histone deacetylase 2)
(3 活性数据)
HDAC10
Tclin
组蛋白去乙酰化酶10(Histone deacetylase 10)
(1 活性数据)
HDAC8
Tclin
组蛋白去乙酰化酶8(Histone deacetylase 8)
(4 活性数据)
HDAC5
Tclin
组蛋白去乙酰化酶5(Histone deacetylase 5)
(3 活性数据)
HDAC3
Tclin
组蛋白去乙酰化酶3(Histone deacetylase 3)
(4 活性数据)
化学和物理性质
溶解性
Solubility (25°C) In vitro 5%TFA 3.04 mg/mL (1.45 mM); DMSO: 0.01 mg/mL (0.0 mM); Water: Insoluble;
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
技术文档和文章
组蛋白去乙酰化酶抑制剂
目录： 技术文章
溶液计算器
常见问题
「Moligand?」是什么？
「Moligand?」是阿拉丁科学的高端产品线之一，专为多个工作流程中的高纯度应用而设计。与同类工作流程中的标准级别相比，「Moligand?」产品通常具有更严格的规格、更严谨的 QC 以及更强的批间一致性。
本产品应如何储存？
请于?80 °C条件下保存。需超低温保存以维持规定的有效期。
本产品如何运输？
本产品采用干冰配冷袋冷冻运输。收货后请立即拆包，并按上述储存条件保存；处理干冰时请戴隔热手套并保持通风。
本产品的 CAS 号、分子式和分子量是多少？
本产品的 CAS 号为 287383-59-9，分子式为 C18H18N2O4，分子量为 326.35 g/mol。
如何获取批次专用COA？
每个订单都会随附分析证书（COA），您也可以从账户订单历史中下载。如需订购前的COA，请联系您的客户代表，或使用PDP上的"申请COA"按钮——我们将提供代表性批次的COA。
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）